Results 121 to 130 of about 547 (137)
Some of the next articles are maybe not open access.
Molecular Pharmaceutics, 2014
The urokinase-type plasminogen activator receptor (uPAR) is implicated in cancer invasion and metastatic development in prostate cancer and provides therefore an attractive molecular target for both imaging and therapy. In this study, we provide the first in vivo data on an antimetastatic effect of uPAR radionuclide targeted therapy in such lesions and
Morten Persson +6 more
semanticscholar +4 more sources
The urokinase-type plasminogen activator receptor (uPAR) is implicated in cancer invasion and metastatic development in prostate cancer and provides therefore an attractive molecular target for both imaging and therapy. In this study, we provide the first in vivo data on an antimetastatic effect of uPAR radionuclide targeted therapy in such lesions and
Morten Persson +6 more
semanticscholar +4 more sources
Cancer Research, 2016
Abstract Objective The urokinase-type plasminogen activator receptor (uPAR) is a well-established prognostic biomarker in many cancer types including breast cancer (BC). Numerous studies using immunohistochemically evaluation of uPAR expression in tissue samples from BC patients have shown that not only is uPAR ...
A. Kjaer +10 more
semanticscholar +2 more sources
Abstract Objective The urokinase-type plasminogen activator receptor (uPAR) is a well-established prognostic biomarker in many cancer types including breast cancer (BC). Numerous studies using immunohistochemically evaluation of uPAR expression in tissue samples from BC patients have shown that not only is uPAR ...
A. Kjaer +10 more
semanticscholar +2 more sources
Nuclear Medicine and Biology, 2012
The proposition of uPAR as a potential target in cancer therapy is advanced by its predominant expression at the invasive front of colorectal cancer (CRC) and its value as prognostic biomarker for poor survival in this disease. In this study, we provide the first in vivo proof-of-concept for a theranostic approach as treatment modality in a human ...
Morten Persson +4 more
semanticscholar +4 more sources
The proposition of uPAR as a potential target in cancer therapy is advanced by its predominant expression at the invasive front of colorectal cancer (CRC) and its value as prognostic biomarker for poor survival in this disease. In this study, we provide the first in vivo proof-of-concept for a theranostic approach as treatment modality in a human ...
Morten Persson +4 more
semanticscholar +4 more sources
2025 IEEE Nuclear Science Symposium (NSS), Medical Imaging Conference (MIC) and Room Temperature Semiconductor Detector Conference (RTSD)
[${ }^{68}\text{Ga}]\text{Ga-NOTA-AE105}$ Positron Emission Tomography (PET) targeting urokinase-type plasminogen activator receptor (uPAR) has shown promise for noninvasive assessment of prostate cancer aggressiveness.
J. V. Mortensen +6 more
semanticscholar +1 more source
[${ }^{68}\text{Ga}]\text{Ga-NOTA-AE105}$ Positron Emission Tomography (PET) targeting urokinase-type plasminogen activator receptor (uPAR) has shown promise for noninvasive assessment of prostate cancer aggressiveness.
J. V. Mortensen +6 more
semanticscholar +1 more source
Chemistry, 2023
Urokinase-type plasminogen activator receptor (uPAR) is a glycolipid-anchored protein located on the cell surface that is implicated in the promotion of metastasis. New fluorescent probes for the detection of uPAR expression that feature a rapid "turn-on"
Tae-Il Kim +3 more
semanticscholar +1 more source
Urokinase-type plasminogen activator receptor (uPAR) is a glycolipid-anchored protein located on the cell surface that is implicated in the promotion of metastasis. New fluorescent probes for the detection of uPAR expression that feature a rapid "turn-on"
Tae-Il Kim +3 more
semanticscholar +1 more source
PET clinics, 2018
Urokinase plasminogen activator receptor (uPAR) is a key component in proteolysis and extracellular matrix degradation during cancer invasion and metastasis. uPAR overexpression is an important biomarker for aggressiveness in several solid tumors and provides independent clinical information.
Skovgaard, Dorthe +2 more
openaire +2 more sources
Urokinase plasminogen activator receptor (uPAR) is a key component in proteolysis and extracellular matrix degradation during cancer invasion and metastasis. uPAR overexpression is an important biomarker for aggressiveness in several solid tumors and provides independent clinical information.
Skovgaard, Dorthe +2 more
openaire +2 more sources
A Cyclic Peptide-Based Radiotheranostic Agent for Urokinase-Type Plasminogen Activator in Tumors.
ChemistryThe plasminogen activator system is critically involved in tumor progression regulation. Aberrant activation of urokinase-type plasminogen activator (uPA) induces proteolytic degradation of cellular membranes and the extracellular matrix, thereby ...
Kuan Hu +13 more
semanticscholar +1 more source